Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04402138 · ClinicalTrials.gov registry record · Phase 2
Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT04402138 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 15 participants.
The verdict
NCT04402138, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a phase II study to evaluate efficacy of Acalabrutinib as a maintenance therapy following blood or marrow transplant (BMT) in patients who have been diagnosed with mantle cell lymphoma.
Interventions
- DRUG Acalabrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2020-08-07 |
| Est. Completion | 2024-04-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04402138
The ClinicalTrials.gov registry entry for NCT04402138 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Acalabrutinib is the first listed.
NCT04402138 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04402138 about?
NCT04402138 is a clinical study titled "Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma". This is a phase II study to evaluate efficacy of Acalabrutinib as a maintenance therapy following blood or marrow transplant (BMT) in patients who have been diagnosed with mantle cell lymphoma.
What is the current status of trial NCT04402138?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2020-08-07. Estimated completion is 2024-04-05.
What interventions are being tested in trial NCT04402138?
The interventions under investigation include: Acalabrutinib (DRUG).
Who is sponsoring clinical trial NCT04402138?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.